Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

(Reuters) -Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is ...

In April, Verve tweaked the development of the first PCSK9 inhibitor in its programme (VERVE-101) after a trial revealed ...

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the ...

Boston-based Verve Therapeutics is a Nasdaq-traded company focused on genetic medicines for cardiovascular disease.

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular diseaseLilly's established capabilities ...

Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...